1. Volume 383, Issue 9922, Pages 1041-1048 (March 2014)
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS- II): an international, double-blind, randomised placebo-controlled trial 
Prof Jack Cuzick, PhD, Ivana Sestak, PhD, Prof John F Forbes, MD, Prof Mitch Dowsett, PhD, Jill Knox, MSc, Simon Cawthorn, MD, Prof Christobel Saunders, MD, Nicola Roche, MD, Prof Robert E Mansel, MD, Gunter von Minckwitz, MD, Bernardo Bonanni, MD, Tiina Palva, MD, Prof Anthony Howell, MD 
The Lancet 
Volume 383, Issue 9922, Pages (March 2014)
DOI: /S (13)
Copyright © 2014 Cuzick et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
ER=oestrogen receptor. *Could not give family history to establish whether high risk.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Cuzick et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2 Analyses by type of breast cancer
Numbers in subgroups do not match totals because of missing data. ER=oestrogen receptor.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Cuzick et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3
Cumulative incidence of all breast cancers and of invasive ER-positive breast cancers
ER=oestrogen receptor.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Cuzick et al. Open Access article distributed under the terms of CC BY Terms and Conditions

5. Figure 4 Analyses by invasive breast cancer characteristics
Numbers in subgroups do not match totals because of missing data. *Assessed at local laboratories.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Cuzick et al. Open Access article distributed under the terms of CC BY Terms and Conditions

6. Figure 5 Subgroup comparisons
*Cumulative risk calculated with Cox proportional hazards model.
The Lancet  , DOI: ( /S (13) )
Copyright © 2014 Cuzick et al. Open Access article distributed under the terms of CC BY Terms and Conditions